These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 36592291)
1. Minimal symptom expression achievement over time in generalized myasthenia gravis. Uzawa A; Ozawa Y; Yasuda M; Onishi Y; Akamine H; Kuwabara S Acta Neurol Belg; 2023 Jun; 123(3):979-982. PubMed ID: 36592291 [TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes and prognostic factors in generalized myasthenia gravis. Ozawa Y; Uzawa A; Yasuda M; Kojima Y; Onishi Y; Oda F; Kanai T; Himuro K; Kawaguchi N; Kuwabara S J Neurol; 2021 Oct; 268(10):3781-3788. PubMed ID: 33774750 [TBL] [Abstract][Full Text] [Related]
3. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis. Zhao R; Wang Y; Huan X; Zhong H; Zhou Z; Xi J; Da Y; Lei L; Chang T; Ruan Z; Luo L; Li S; Yang H; Li Y; Luo S; Zhao C J Transl Med; 2021 Jun; 19(1):285. PubMed ID: 34193193 [TBL] [Abstract][Full Text] [Related]
4. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF; J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108 [TBL] [Abstract][Full Text] [Related]
6. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Kupersmith MJ; Latkany R; Homel P Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710 [TBL] [Abstract][Full Text] [Related]
7. One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry. Lee I; Leach JM; Aban I; McPherson T; Duda PW; Cutter G Muscle Nerve; 2022 Oct; 66(4):411-420. PubMed ID: 35673964 [TBL] [Abstract][Full Text] [Related]